Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide

Abstract

Aim: To gain insight into the histopathological responses and molecular targets in the inhibition of growth of human gastric cancer treated with celecoxib (a cyclooxygenase [COX]‐2 inhibitor) combined with octreotide. Methods: Seventy five patients with gastric cancer undergoing curative gastrectomy or extended resection were randomly divided into 3 groups. The apoptosis of tumor cells was measured by terminal deoxynucleotide transferase‐mediated dUTP nick end‐labeling (TUNEL) assay. Gastric cancer microvessel density (MVD) and the expression of COX‐2 were evaluated by immunohistochemical staining. The expression of somatostatin receptor (SSTR)‐2 was detected with the biomolecular interaction analysis system. The transcription of non‐steroidal anti‐inflammatory drug‐activated gene (NAG)‐1 was measured by RT‐PCR. Results: Compared with the control and celecoxib groups, more necrosis in the combination group was observed. The apoptotic rate in the combination group (7.06%±0.67%) was significantly higher than that in the control group (6.23%±1.29%, P<0.05). The MVD decreased considerably in the combination group. The upregulation of NAG‐1 was displayed both in the celecoxib and combination groups. The positive rate of SSTR‐2 in gastric cancers treated with celecoxib (48%) was significantly higher than that of control group (12%) after surgery (P<0.05). Conclusion: Celecoxib combined with octreotide significantly promoted necrosis in gastric adenocarci‐noma through the induction of apoptosis and the reduction of MVD. NAG‐1 and SSTR‐2 might be the molecular targets for celecoxib or octreotide.

Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells

“…Many studies have shown that COX-2 is involved in inhibition of apoptosis, potentiation of cell growth, and angiogenesis in familial adenomatous polyposis, esophageal cancer, gastric cancer, lung cancer, and urinary bladder cancers, etc., and as such is a target for drug development of selective COX-2 inhibitors [17][18][19][20].…”

Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors

“…Furthermore, rofecoxib and octreotide were found to have synergic antineoplastic effects in vitro in SGC-7901 cells (a gastric cancer cell line) and in xenografts in nude mice [17], and human gastric adenocarcinoma growth was found to be inhibited preoperatively by a combination of celecoxib and octreotide [18]. …”

The Concentration of Iodine in Perigastric Adipose Tissue: A Novel Index for the Assessment of Serosal Invasion in Patients with Gastric Cancer after Neoadjuvant Chemotherapy

“…In this study, we found out that the accuracy of IC PAT in identifying SI was 9.5–11.2% higher than the conventional CT examination [6]. We speculated that effective NAC could reduce IC PAT by inhibiting the growth of blood vessels in gastric serosa and surrounding fat tissues [24, 25]. Moreover, we attempted to explore the diagnosis value of IC PAT in identifying post-NAC SI in AGC patients.…”